Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 2 Neuroblastoma 2 Meningioma 2 Medulloblastoma 2 Small Cell Lung Carcinoma 1 Recurrence 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 58 Dexamethasone 50 Rituximab 39 Peripheral Blood Stem Cell Transplantation 29 Paclitaxel 29 Lenalidomide 28 fludarabine phosphate 27 Gemcitabine 26 Etoposide 26 Bortezomib 26 Cytarabine 25 Busulfan 24 pembrolizumab 21 Radiotherapy 21 Bevacizumab 21 Carboplatin 20 Mycophenolic Acid 19 Melphalan 19 Cisplatin 19 Filgrastim 18 pomalidomide 17 fludarabine 17 Oxaliplatin 17 Antilymphocyte Serum 17 Cyclosporine 16 Tacrolimus 15 Methotrexate 15 Whole-Body Irradiation 14 Methylprednisolone 13 Bendamustine Hydrochloride 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recurrence × 90Y-octreotide, DOTA-Tyr(3)- × Clear all

NCT02488512 2018-03-19

itTRIOlym

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡